PROBE: Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer

Kadcyla (ado-trastuzumab emtansine) - Roche

Elahere (mirvetuximab soravtansine-gynx) - AbbVie

Padcev (enfortumab vedotin-ejfv) - Astellas, Pfizer

Trodelvy (sacituzumab govitecan-hziy) - Gilead

Datroway (datopotamab deruxtecan-dlnk) - Daiichi Sankyo, AstraZeneca

Enhertu (fam-trastuzumab deruxtecan-nxki) - Daiichi Sankyo, AstraZeneca

izalontamab brengitecan (BL-B01D1) - Sichuan Biokin Pharmaceutical, BMS, Systimmune

Meiyouheng (becotatug vedotin) - Lepu Biopharma

PROBE: Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer (clinicaltrials.gov) - Sep 18, 2026 - P2 | N=225 | Not yet recruiting | Sponsor: Fudan University
New P2 trial • Breast Cancer • HER2 Positive Breast Cancer • Oncology • Pancreatic Cancer • Solid Tumor • ER • PGR

http://clinicaltrials.gov/ct2/show/NCT07825753

Sep 18, 2026